136516-64-8

Basic information

• Product Name: Benzaldehyde, 2,4-difluoro-6-hydroxy- (9CI)
• Synonyms: Benzaldehyde, 2,4-difluoro-6-hydroxy- (9CI);4,6-Difluoro-2-hydroxybenzaldehyde;Benzaldehyde, 2,4-difluoro-6-hydroxy-
• CAS NO: 136516-64-8
• Molecular Formula: C₇H₄F₂O₂
• Molecular Weight: 158.1022664
• EINECS: 1533716-785-6
• Product Categories: ALDEHYDE
• Mol File: 136516-64-8.mol

Chemical Properties

• Melting Point: 32℃
• Boiling Point: 207.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.464±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 6.18±0.15(Predicted)
• CAS DataBase Reference: Benzaldehyde, 2,4-difluoro-6-hydroxy- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzaldehyde, 2,4-difluoro-6-hydroxy- (9CI)(136516-64-8)
• EPA Substance Registry System: Benzaldehyde, 2,4-difluoro-6-hydroxy- (9CI)(136516-64-8)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 136516-64-8(Hazardous Substances Data)

Usage

Uses

Used in Flavoring Industry:
Benzaldehyde, 2,4-difluoro-6-hydroxy(9CI) is used as a flavoring agent for its distinctive sweet almond-like aroma, enhancing the taste profiles of various food products.
Used in Perfumery:
Benzaldehyde, 2,4-difluoro-6-hydroxy(9CI) is utilized in the perfume industry to contribute to the creation of fragrances, capitalizing on its aromatic properties.
Used in Dye Manufacturing:
Benzaldehyde, 2,4-difluoro-6-hydroxy(9CI) is employed in the production of dyes, where its chemical structure plays a role in color development and stability.
Used in Pharmaceutical Industry:
It is used as a building block in the synthesis of drug molecules, indicating its importance in medicinal chemistry for developing new therapeutic agents.
However, it is crucial to handle Benzaldehyde, 2,4-difluoro-6-hydroxy(9CI) with care due to its potential health hazards. Prolonged exposure or high levels of contact with Benzaldehyde, 2,4-difluoro-6-hydroxy- (9CI) can result in irritation to the eyes, skin, and respiratory system, emphasizing the need for proper safety measures during its use in various applications.

Upstream product

• 50-00-0 formaldehyd 
• 2713-34-0 3,5-difluorophenol 
• 608515-57-7 2,4-difluoro-6-methoxybenzaldehyde 
• 899427-17-9 (3,5-difluorophenyl) N-isopropylcarbamate 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1209492-98-7 2-(allyloxy)-4,6-difluorobenzaldehyde 
• 1446332-78-0 tert-butyl 4-(3-fluoro-4-formyl-5-hydroxyphenyl)piperazine-1-carboxylate 
• 1446330-28-4 3-(3,5-difluorophenyl)-5-fluoro-7-(piperazin-1-yl)-2H-chromen-2-one 
• 1446332-82-6 tert-butyl 4-(3-(3,5-difluorophenyl)-5-fluoro-2-oxo-2H-chromen-7-yl)piperazine-1-carboxylate 
• 608515-58-8 2,4-difluoro-6-prop-1-ynylbenzaldehyde 

Relevant articles and documents

Efficient two-step synthesis of salicylaldehydes via directed ortho-lithiation of in situ N-silylated O-aryl N-isopropylcarbamates

O-Aryl N-isopropylcarbamates, conveniently prepared from phenols and isopropyl isocyanate, are subjected to an efficient ortho-lithiation protocol to afford the corresponding salicylaldehydes in a one-pot operation in high yields. Georg Thieme Verlag Stuttgart.

CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.

Compounds for treating spinal muscular atrophy

Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.

COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY

Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.

Structure based drug design: Development of potent and selective factor IXa (FIXa) inhibitor

On the basis of our understanding on the binding interactions of the benzothiophene template within the FIXa active site by X-ray crystallography and molecular modeling studies, we developed our SAR strategy by targeting the 4-position of the template to access the S1 β and S2-S4 sites. A number of highly selective and potent, factor Xa (FXa) and FIXa inhibitors were identified by simple switch of functional groups with conformational changes toward the S2-S4 sites.

Non-metallocene compounds, method for the production thereof and use of the same for the polymerisation of olefins

The invention relates to a method for producing special transition metal compounds, to novel transition metal compounds and to the use of the same for the polymerisation of olefins.

AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN

the present invention provides a compound of formula (I): wherein V represents NR5, O, S, SO or S(O)2; W and X each independently represent CH or N; Y represents N, CH or C-Ar2, with the proviso that at least one, but no more than two, of W, X and Y are N; Z represents CH or C-Ar2, with the proviso that when Y is N or CH then Z is C-Ar2, and with the further proviso that when Y is C-Ar2 then Z is CH; Ar1 represents a fused 9 or 10 membered heterobicyclic ring system containing one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, wherein at least one of the rings in said ring system is aromatic; Ar2 represents an aromatic ring selected from phenyl, pyridyl, pyrimidinyl and pyridazinyl which is optionally fused and substituted; R1 represents halogen, hydroxy, oxo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkoxy, C3-7cycloalkyl, C3-7cycloalkoxy, C3-5cycloalkylC1-4alkyl, cyano, nitro, SR6, SOR6, SO2R6, COR6, NR3COR6, CONR3R4, NR3SO2R6, SO2NR3R4, -(CH2)mcarboxy, esterified -(CH2)mcarboxy or -(CH2)mNR3R4; R2 represents hydrogen, halogen, hydroxy, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy, haloC1-6alkoxy, unsubstituted phenyl or phenyl substituted with one or two groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or haloC1-6alkoxy; R3 and R4 are each independently hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl or fluoroC1-6alkyl; or R3 and R4 and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C1-4alkoxy, which ring may optionally contain as one of the said ring atoms an oxygen or a sulfur atom, S(O), S(O)2, or NR5; R5 represents hydrogen, C1-4alkyl, hydroxyC1-4alkyl or C1-4alkoxyC1-4alkyl; R6 represents hydrogen, C1-6alkyl, fluoroC1-6alkyl, C3-7cycloalkyl, unsubstituted phenyl, or phenyl substituted with one or two groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or haloC1-6alkoxy; m is either zero or an integer from 1 to 4; n is either zero or an integer from 1 to 3; or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof; a pharmaceutical composition comprising it; its use in methods of treatment; use of it for the manufacture of a medicament for treating VR-1 related conditions such as those in which pain and/or inflammation predominate; and methods of treatment using it.